<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109352">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02027064</url>
  </required_header>
  <id_info>
    <org_study_id>PUPH IRB [2013](38)</org_study_id>
    <nct_id>NCT02027064</nct_id>
  </id_info>
  <brief_title>Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      molecular relapse in t (8; 21) acute myeloid leukemia (AML) after allogeneic stem cell
      transplantation (allo-SCT) is still a problem even after donor lymphocyte infusion.

      Interferon seemed to augment graft-versus-leukemia (GVL) effect in this part of patients.

      the study is to evaluate the safety and efficacy of interferon for the intervention of
      molecular relapse in t (8; 21) acute myeloid leukemia (AML) after allogeneic stem cell
      transplantation (allo-SCT)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>relapse rate</measure>
    <time_frame>participants will be followed for an expected average of 365 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>number of participants with morphologic relapse at one year</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>interferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-alpha</intervention_name>
    <arm_group_label>interferon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  high risk t (8; 21) AML

          -  molecular relapse after allo-SCT

        Exclusion Criteria:

          -  active graft-versus-host disease

          -  uncontrolled severe infection

          -  organ function failure
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>yu wang, M.D.</last_name>
    <phone>861088326666</phone>
    <phone_ext>4952</phone_ext>
    <email>ywyw3172@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yu wang, M.D.</last_name>
      <phone>861088326666</phone>
      <phone_ext>4952</phone_ext>
      <email>ywyw3172@sina.com</email>
    </contact>
    <investigator>
      <last_name>xiao-jun huang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 2, 2014</lastchanged_date>
  <firstreceived_date>January 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Xiaojun Huang</investigator_full_name>
    <investigator_title>director of Peking University People's Hospital, institute of hematology</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon Alfa-2a</mesh_term>
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
